Arylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Pharmacology & Mechanism of Ketamine

Detailed pharmacological information is currently being assembled by our research team.

Quick Facts

  • Highest PhasePhase III
  • Key IndicationsMajor Depressive Disorder (MDD), Treatment-Resistant Depression (TRD)
  • Primary MechanismNMDA Receptor Antagonist
  • Session Duration1-2 hours
  • OriginSynthesised

Connected Research

Recent clinical trials and academic literature investigating Ketamine.

Recent Clinical Trials

View all trials →
Not yet recruitingPhase III

Comparison of Intranasal Ketorolac and Intranasal Ketamine in Digital Nerve Block Pain

RecruitingPhase III

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (AVENUE)

Withdrawn

Effects of acute ketamine administration on mental representations of the body in healthy participants.

Completed

Intranasal dexmedetomidine versus intranasal ketamine for prevention of emergence agitation after sevoflurane anesthesia in pediatric patients undergoing myringotomy : a randomized clinical trial.

CompletedPhase IV

Perioperative Ketamine to Reduce Postoperative Delirium and Depression in elderly patients undergoing cardiac and major vascular surgery (The RECOGNISED Study)

Completed

Effect of Low Dose Ketamine on Postoperative Cognitive Dysfunction in Geriatric Patients Undergoing Abdominal Surgery

Recent Academic Papers

View all papers →

Effect of Esketamine on Depressive Symptoms in Adolescents with Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study

Published
Journal
Journal of the American Academy of Child & Adolescent Psychiatry

Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics

Published
Journal
ACS Chemical Neuroscience

Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study

Published
Journal
Journal of Affective Disorders

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval

Published
Journal
American Journal of Psychiatry

Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial

Published
Journal
JAMA Psychiatry

Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial

Published
Journal
Journal of Affective Disorders